The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 23, 2021

Filed:

Jul. 29, 2019
Applicant:

David Gordon Bermudes, Woodland Hills, CA (US);

Inventor:

David Gordon Bermudes, Woodland Hills, CA (US);

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C12N 15/74 (2006.01); A61K 35/74 (2015.01); C07K 14/81 (2006.01); C07K 14/47 (2006.01); A61K 39/145 (2006.01); A61K 39/02 (2006.01); A61K 39/07 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/74 (2013.01); A61K 35/74 (2013.01); A61K 39/0208 (2013.01); A61K 39/07 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); C07K 14/005 (2013.01); C07K 14/47 (2013.01); C07K 14/81 (2013.01); C07K 14/811 (2013.01); A61K 38/00 (2013.01); A61K 2039/522 (2013.01); A61K 2039/523 (2013.01); A61K 2039/542 (2013.01); C07K 2319/02 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/50 (2013.01); C07K 2319/55 (2013.01); C12N 2760/16134 (2013.01);
Abstract

Chimeric proteins are expressed, secreted or released by a bacterium to immunize against or treat a parasite, infectious disease or malignancy. The delivery vector may also be attenuated, non-pathogenic, low pathogenic, or a probiotic bacterium. The chimeric proteins include chimeras of, e.g., phage coat and/or colicin proteins, bacterial toxins and/or enzymes, autotransporter peptides, lytic peptides, multimerization domains, and/or membrane transducing (ferry) peptides. The active portion of the immunogenic chimeric proteins can include antigens against a wide range of parasites and infectious agents, cancers, Alzheimer's and Huntington's diseases, and have enhanced activity when secreted or released by the bacteria, and/or have direct anti-parasite or infectious agent activity. The activity of the secreted proteins is further increased by co-expression of a protease inhibitor that prevents degradation of the effector peptides. Addition of an antibody binding or antibody-degrading protein further prevents the premature elimination of the vector and enhances the immune response.


Find Patent Forward Citations

Loading…